Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (78 reviews)

For research use only. Not for use in humans.

Catalog No.S1091

78 publications

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 78 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 539(7630):570-574

PubMed: 27820945 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )
J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )
Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	NUPQc5FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzQTJBKSzVyPUCuNFI5ODZizszN	NX3WeJpOW0GQR1XS
KS-1	M{PVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\ZNmlEPTB;MD6wN\|g{PSEQvF2=	MVzTRW5ITVJ?
TE-11	NFPi[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rBTWlEPTB;MD6wO\|gzOiEQvF2=	MnzJV2FPT0WU
EW-1	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMEi1PFUh\|ryP	NInYcpRUSU6JRWK=
HMV-II	M2DoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEi4OFYh\|ryP	NXrXW406W0GQR1XS
COLO-205	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7K[HNKSzVyPUCuNVA1PTRizszN	MkPXV2FPT0WU
ES1	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMUC2PVYh\|ryP	M2TIV3NCVkeHUh?=
GDM-1	M{WzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LGbGlEPTB;MD6xN\|Y4OiEQvF2=	MXLTRW5ITVJ?
ML-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG2S2w6UUN3ME2wMlE2QDl4IN88US=>	NWWzeYR{W0GQR1XS
Saos-2	M33SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDwZpBQUUN3ME2wMlE3PTJ4IN88US=>	M3zPO3NCVkeHUh?=
NCI-H1355	M2DRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUixN\|Uh\|ryP	M1H0ZnNCVkeHUh?=
G-401	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXkTGFKSzVyPUCuNVgzOyEQvF2=	MWXTRW5ITVJ?
EW-16	M3zyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMUi3O\|ch\|ryP	NFTjPYVUSU6JRWK=
EW-7	M{jtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjERVVKSzVyPUCuNVg5QDFizszN	NUC3bXBXW0GQR1XS
NCI-H727	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMUm3PVQh\|ryP	M3;uZXNCVkeHUh?=
LCLC-97TM1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\xUmlEPTB;MD6yNFk2PSEQvF2=	MVjTRW5ITVJ?
NCI-H650	M3HNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13STGlEPTB;MD6yNVM5PCEQvF2=	MUTTRW5ITVJ?
NCI-H2122	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLYTWM2OD1yLkKzNlk6KM7:TR?=	MkHaV2FPT0WU
SK-N-DZ	M{TQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMkO2PVgh\|ryP	M1rZWnNCVkeHUh?=
HT-29	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrHTWM2OD1yLkK0NlQ5KM7:TR?=	M4TtfnNCVkeHUh?=
LB771-HNC	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnMS4FFUUN3ME2wMlI2QTF3IN88US=>	M{jmXHNCVkeHUh?=
HT-144	NFzke4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\qTWM2OD1yLkK2NVkyKM7:TR?=	NGGyfI1USU6JRWK=
LAN-6	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT5RmlKSzVyPUCuNlY{PDhizszN	MkfDV2FPT0WU
EW-18	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1qyfWlEPTB;MD6yO\|AxOSEQvF2=	NXvrT2s4W0GQR1XS
LS-1034	NWnYUZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPLTWM2OD1yLkK3NVMzKM7:TR?=	M1PERnNCVkeHUh?=
EW-11	M2LUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfVTWM2OD1yLkK4OFMzKM7:TR?=	M{fHZnNCVkeHUh?=
SNU-C1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HBWGlEPTB;MD6yPVMyOyEQvF2=	Mn\VV2FPT0WU
RS4-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HEdGlEPTB;MD6zN\|c2QCEQvF2=	NEfUSGlUSU6JRWK=
ES4	NHTVeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jKcGlEPTB;MD60NVA{QCEQvF2=	MYfTRW5ITVJ?
COLO-320-HSR	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHu4RW9KSzVyPUCuOFE{PjhizszN	M1XHbnNCVkeHUh?=
NB10	NGLxT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjYdGRKSzVyPUCuOFU1OzdizszN	MnLIV2FPT0WU
BFTC-905	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGGycpNKSzVyPUCuOFY4PThizszN	MUjTRW5ITVJ?
A375	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonZTWM2OD1yLkS3OlE4KM7:TR?=	MX7TRW5ITVJ?
SJRH30	NYDhVpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjrVVR5UUN3ME2wMlUxQDJ{IN88US=>	NEDXfVNUSU6JRWK=
NOS-1	NV\IZnZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[2TWM2OD1yLkWyNlY4KM7:TR?=	M{jld3NCVkeHUh?=
SIG-M5	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1uyNGlEPTB;MD61N\|U2PyEQvF2=	M{fhUXNCVkeHUh?=
DOK	NYPOd2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnz4TWM2OD1yLkW1OkDPxE1?	M3qycXNCVkeHUh?=
NB69	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz4RmxXUUN3ME2wMlU5OjV5IN88US=>	NUHNRYZ{W0GQR1XS
SK-NEP-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwNkCyN\|Yh\|ryP	MVfTRW5ITVJ?
SK-MM-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13YVmlEPTB;MD62OVQ6OSEQvF2=	MXLTRW5ITVJ?
NCI-H358	NYHFR21JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwNkewPFIh\|ryP	MoDUV2FPT0WU
RH-1	NYqxPXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkixTWM2OD1yLke0PFU6KM7:TR?=	MojFV2FPT0WU
NH-12	NH7lTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD5R\|VEUUN3ME2wMlc3ODR4IN88US=>	MVPTRW5ITVJ?
TE-12	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHkS\|hiUUN3ME2wMlc3PDh4IN88US=>	MoXxV2FPT0WU
COLO-668	NV3tVHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPVTWM2OD1yLki0OlY3KM7:TR?=	MVHTRW5ITVJ?
PANC-08-13	NGfuZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnW0TWM2OD1yLki2N\|c4KM7:TR?=	MYrTRW5ITVJ?
HCC2998	NFPFfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz6O4l7UUN3ME2wMlg5OjZ\|IN88US=>	M{HWdXNCVkeHUh?=
ABC-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXpeFU5UUN3ME2wMlkxOzV{IN88US=>	MkjRV2FPT0WU
ES6	M4SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHoTWM2OD1yLkmxNFY3KM7:TR?=	NF\vVFZUSU6JRWK=
SNU-387	NETtW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjZTWM2OD1yLkm5N\|k{KM7:TR?=	MYLTRW5ITVJ?
CMK	NVnVOolPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjvTWM2OD1yLkm5PVI6KM7:TR?=	MVvTRW5ITVJ?
SJSA-1	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTMUpZZUUN3ME2xMlA{PjV\|IN88US=>	MVfTRW5ITVJ?
SIMA	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fQUWlEPTB;MT6wOlgzPSEQvF2=	Ml;TV2FPT0WU
ES3	M2q0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DVWGlEPTB;MT6xNlI6PyEQvF2=	NV3XUVR7W0GQR1XS
IGROV-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e2PGlEPTB;MT6xOVQ1PCEQvF2=	MkixV2FPT0WU
MEL-JUSO	NWXyZm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nxR2lEPTB;MT6xOVc2QSEQvF2=	MWnTRW5ITVJ?
T84	MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XGcGlEPTB;MT6yNFkyPCEQvF2=	MnzNV2FPT0WU
CAL-85-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LoWmlEPTB;MT6yN\|E{QCEQvF2=	MV\TRW5ITVJ?
RD	Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDxXHlKSzVyPUGuNlY1PTVizszN	M{fuOHNCVkeHUh?=
TE-8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPpN5RQUUN3ME2xMlMyPDZ{IN88US=>	MYXTRW5ITVJ?
L-363	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTFwM{SyNFgh\|ryP	NVjFVHhmW0GQR1XS
EKVX	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG5TWM2OD1zLkO0OVY5KM7:TR?=	MXnTRW5ITVJ?
SK-MEL-3	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwNEi1OVYh\|ryP	MoDvV2FPT0WU
TGBC24TKB	M1Hmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXHOHg2UUN3ME2xMlUxOTl\|IN88US=>	M1LEUnNCVkeHUh?=
NCI-H1770	M{n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Lr[GlEPTB;MT61NVEyOyEQvF2=	MWLTRW5ITVJ?
HuH-7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn6dWh2UUN3ME2xMlYxODl6IN88US=>	NECxW\|hUSU6JRWK=
HL-60	NX;1[JBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTFwNk[5Nlgh\|ryP	NXvDRm5iW0GQR1XS
TE-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFwN{C5OFUh\|ryP	Mn\EV2FPT0WU
LC-2-ad	M3\sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT6TWM2OD1zLkezPFg4KM7:TR?=	M4m2V3NCVkeHUh?=
LB647-SCLC	M4PpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwN{[1PFMh\|ryP	MoPYV2FPT0WU
NCI-H2171	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXuTWM2OD1zLke3O\|E3KM7:TR?=	MlPpV2FPT0WU
SK-PN-DW	NYnQSlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLBOWNKSzVyPUGuPVEzQThizszN	NULoVYZHW0GQR1XS
MC-IXC	NEjQfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHtTohJUUN3ME2xMlk5QThizszN	MWfTRW5ITVJ?
LS-513	MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7ITWM2OD1{LkC1N\|A2KM7:TR?=	MX;TRW5ITVJ?
EW-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJwMEm4OFQh\|ryP	NWPidYlDW0GQR1XS
OPM-2	NInaSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nDZWlEPTB;Mj6xNFIh\|ryP	NETsUW1USU6JRWK=
LP-1	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfkWmdKSzVyPUKuNlU5ODdizszN	MX;TRW5ITVJ?
LU-134-A	NEPOOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XhUWlEPTB;Mj6yO\|ch\|ryP	MYHTRW5ITVJ?
CP66-MEL	NV65NIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\WTWM2OD1{LkK5NFE1KM7:TR?=	M{DyR3NCVkeHUh?=
HCC1143	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHSTWM2OD1{LkS1N\|Y5KM7:TR?=	NVv2UWxIW0GQR1XS
LOXIMVI	NXvMbYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4KzVWlEPTB;Mj62NFIyKM7:TR?=	MYfTRW5ITVJ?
TE-10	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrKOHNKSzVyPUKuO\|A5OzhizszN	NHi4ZVRUSU6JRWK=
NCI-H1882	NX\tXGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJwN{WyNlch\|ryP	M{TWb3NCVkeHUh?=
CHP-126	NVTkeHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjTTWM2OD1{Lke2N\|E4KM7:TR?=	MoH2V2FPT0WU
NCI-H1623	NGTWW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorsTWM2OD1{LkmyNFI1KM7:TR?=	M1m5UnNCVkeHUh?=
GB-1	NIixcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHrTWM2OD1{LkmzOFA1KM7:TR?=	NUTkcG9QW0GQR1XS
RCC10RGB	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[w[mY1UUN3ME2yMlk2OjhzIN88US=>	NFXMUmdUSU6JRWK=
NCI-H2141	NI[3WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTJwOU[4PVYh\|ryP	NHXFcXpUSU6JRWK=
GI-ME-N	NUTKdJBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTNwMEC1OlUh\|ryP	MnTmV2FPT0WU
NCI-H526	NVXueINRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTNwMESwPFUh\|ryP	Mlv1V2FPT0WU
NCI-H747	NWXPc2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XYPWlEPTB;Mz6wOFk6OiEQvF2=	M1yyUHNCVkeHUh?=
SNU-423	NHLvOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTNwMkCzNVMh\|ryP	M1rvN3NCVkeHUh?=
A427	NV3yOmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTNwMkW2PVkh\|ryP	M3XOS3NCVkeHUh?=
CAL-12T	NIDZSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTNwNEC3NVMh\|ryP	M2HxRXNCVkeHUh?=
LU-99A	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzq[YpGUUN3ME2zMlQ4OTB3IN88US=>	MU\TRW5ITVJ?
MS-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTNwNUO0Nlkh\|ryP	MXTTRW5ITVJ?
SK-LU-1	NV\XbWpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS4TWM2OD1\|Lke2Nlk2KM7:TR?=	M{m5WXNCVkeHUh?=
SW837	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vuVmlEPTB;Mz63OlM{OyEQvF2=	M4\Ke3NCVkeHUh?=
ES8	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PaPGlEPTB;Mz64N\|g4PyEQvF2=	M1rEUHNCVkeHUh?=
MZ2-MEL	NGrPV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTmTWM2OD1\|LkmyNFg3KM7:TR?=	M4rPWXNCVkeHUh?=
TGW	M1TNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXKzelF{UUN3ME20MlAyOzFzIN88US=>	NX3WXYF3W0GQR1XS
GP5d	NFHiTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\X[JRKSzVyPUSuNFU{PjJizszN	NWGyVlNrW0GQR1XS
BB49-HNC	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnkWnNKSzVyPUSuNVUzOTNizszN	MVPTRW5ITVJ?
NB13	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInDWoRKSzVyPUSuNlY5QDdizszN	NIjXO4ZUSU6JRWK=
NTERA-S-cl-D1	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\HTWM2OD12LkK4OlE2KM7:TR?=	NUnPRnQ{W0GQR1XS
NCI-H1648	NF:1VmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vwc2lEPTB;ND6yPVgyQSEQvF2=	MWrTRW5ITVJ?
LCLC-103H	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DxOmlEPTB;ND6zNlE6PSEQvF2=	Ml[zV2FPT0WU
LS-411N	NUPhUWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTRwNES4PFUh\|ryP	M2jvVnNCVkeHUh?=
NCI-H1092	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTuZnFKSzVyPUSuOFU3QDdizszN	Ml:wV2FPT0WU
PANC-10-05	NILPbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnx[WdKSzVyPUSuOlk5PCEQvF2=	MWXTRW5ITVJ?
DK-MG	NGTtRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPyTWM2OD12LkiwPVM{KM7:TR?=	Mo\JV2FPT0WU
OVCAR-5	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\jUXI3UUN3ME20MlgyOjJ4IN88US=>	NXv3NnFLW0GQR1XS
CAL-39	M1;u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XDPGlEPTB;ND64O\|Y4KM7:TR?=	M{\We3NCVkeHUh?=
TE-441-T	NWWwSJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DhXGlEPTB;ND65NFU{PyEQvF2=	MUjTRW5ITVJ?
MOLT-16	MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PIPWlEPTB;ND65OVI2OyEQvF2=	Mlv1V2FPT0WU
MCF7	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTVwMUS1NVch\|ryP	NETWeFZUSU6JRWK=
CAPAN-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTVwMkW3NFch\|ryP	NF\qb3RUSU6JRWK=
PSN1	M{[2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrTcYhTUUN3ME21MlI4OjN3IN88US=>	MnzhV2FPT0WU
NCI-H292	NVHtXIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTVwM{CwOFQh\|ryP	NHHiWXpUSU6JRWK=
CPC-N	NHW1[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13YZmlEPTB;NT6zPVQyQSEQvF2=	M4LaWHNCVkeHUh?=
DoTc2-4510	M1HEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j5Z2lEPTB;NT60OVM4OSEQvF2=	NV;RdolwW0GQR1XS
LB1047-RCC	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\6b2lEPTB;NT61OVk{OyEQvF2=	MUfTRW5ITVJ?
MHH-ES-1	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrxb2xKSzVyPUWuOVk6ODdizszN	MXPTRW5ITVJ?
NMC-G1	NXzjdlVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTVwN{CyNlch\|ryP	MUHTRW5ITVJ?
SW1710	NXLafHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\DfFFKSzVyPUWuO\|Q4PTFizszN	NYf4OphCW0GQR1XS
YAPC	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnOcm85UUN3ME21Mlc3OjBzIN88US=>	MYDTRW5ITVJ?
22RV1	M3\ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW1dlVKSzVyPUWuPFAxOTlizszN	NELCeHdUSU6JRWK=
COLO-679	NVPaUXJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTVwOEi5OFgh\|ryP	M2XQd3NCVkeHUh?=
TCCSUP	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTuTWM2OD13LkmzNlU6KM7:TR?=	MknTV2FPT0WU
C2BBe1	NEnpeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHuTWM2OD13LkmzPVch\|ryP	M1;TPHNCVkeHUh?=
TE-15	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTZwME[2NFUh\|ryP	NEPpe\|FUSU6JRWK=
SCLC-21H	NYiz[HR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:4V2lEPTB;Nj6xNFg1OyEQvF2=	M1z0e3NCVkeHUh?=
EoL-1-cell	NGOwUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzyXGxSUUN3ME22MlE3PTZ\|IN88US=>	MmTsV2FPT0WU
NKM-1	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPITWM2OD14LkG2O\|Eh\|ryP	MkHrV2FPT0WU
NCI-H1304	NYSyeXB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XXfWlEPTB;Nj6yO\|QzQCEQvF2=	NEDNVGRUSU6JRWK=
NB6	M2DSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{f6N2lEPTB;Nj6yPVYzOiEQvF2=	NXnieJl5W0GQR1XS
NALM-6	NUTYfWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTZwM{OyN{DPxE1?	NYrjR3l3W0GQR1XS
NCI-H522	M1vVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17Ye2lEPTB;Nj6zN\|MxPiEQvF2=	MmHYV2FPT0WU
MV-4-11	NXLoZnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;0TWM2OD14LkO3NFc6KM7:TR?=	NI\yeXRUSU6JRWK=
LB2241-RCC	NIXQdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki1TWM2OD14LkO4OlY4KM7:TR?=	NXHHS5I1W0GQR1XS
NCI-H1417	NXTI[GtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTZwNEC4OFch\|ryP	NYKwVWw1W0GQR1XS
HT-1197	M3rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfqTWM2OD14LkW3NVIzKM7:TR?=	MWjTRW5ITVJ?
P30-OHK	M1vqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHK2WHdKSzVyPU[uOlI4PyEQvF2=	NXv0Z5l3W0GQR1XS
ALL-PO	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTZwN{G5NVYh\|ryP	MlXiV2FPT0WU
OVCAR-4	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnPN\|A3UUN3ME22Mlc2PDB3IN88US=>	NIfQVJZUSU6JRWK=
HCC2157	NXm2[G5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTZwN{e0O\|Uh\|ryP	NHrGdXdUSU6JRWK=
NCI-H838	M122PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPxTWM2OD14Lkm2OFkh\|ryP	M2fXNHNCVkeHUh?=
NCI-H1299	M{\KPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:2eoJmUUN3ME22Mlk4ODlizszN	MXvTRW5ITVJ?
SW954	NIfkU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7KTWM2OD15LkKwNFY5KM7:TR?=	NVfXRWJjW0GQR1XS
NCI-H441	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zFfGlEPTB;Nz6zOFA3PSEQvF2=	NE\CdYVUSU6JRWK=
SK-MEL-2	M4rnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLF[5AzUUN3ME23MlQ5Ozd\|IN88US=>	NIfnV2lUSU6JRWK=
KARPAS-45	NYjPTlhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTdwNkW5Nlkh\|ryP	NGSxe3pUSU6JRWK=
CAL-54	NHXidJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDmSI9zUUN3ME23MlgzQTd5IN88US=>	M1TVR3NCVkeHUh?=
KYSE-180	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\NdGlEPTB;Nz64PFk1OSEQvF2=	NIPHWZVUSU6JRWK=
NCI-H187	NW\t[ZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnM[mJFUUN3ME23Mlk2QTR5IN88US=>	NULtOXRZW0GQR1XS
RT-112	NGDSZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1SwN2lEPTB;OD6wPVY4PyEQvF2=	MoPjV2FPT0WU
NCI-H1437	NUftPGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf4ZoJRUUN3ME24MlA6Pzl3IN88US=>	NG\UcIlUSU6JRWK=
SNU-449	NWnSOWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRThwMkiyO\|Ih\|ryP	MnnhV2FPT0WU
HCC1187	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRThwMkmzPVEh\|ryP	M4WwPHNCVkeHUh?=
NCI-H2030	NWOycnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRThwM{e3NVQh\|ryP	MmW4V2FPT0WU
HuO-3N1	NY\pSW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHjWlFKSzVyPUiuN\|c5PDRizszN	M2nMZXNCVkeHUh?=
COLO-792	NH;qeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRThwNEG1Nlch\|ryP	M1fqTHNCVkeHUh?=
MIA-PaCa-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3L0O2lEPTB;OD64OVUxQCEQvF2=	NFXWSYNUSU6JRWK=
SK-N-FI	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37tbGlEPTB;OT6wOFI2KM7:TR?=	NFL4PJRUSU6JRWK=
MMAC-SF	M4H0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoC4TWM2OD17LkC5O\|UyKM7:TR?=	M1vpXnNCVkeHUh?=
NCI-H28	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHK4WopKSzVyPUmuNVA1PjlizszN	NHP3UnhUSU6JRWK=
ETK-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTuTWM2OD17LkK5PVc1KM7:TR?=	NIDCboJUSU6JRWK=
NCI-H1993	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETMcpNKSzVyPUmuOFQzPjFizszN	MnnBV2FPT0WU
no-11	NHvMem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rIV2lEPTB;OT60O\|EzKM7:TR?=	NVPhVlFlW0GQR1XS
ChaGo-K-1	NG\uOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTlwNUG1PFMh\|ryP	NY\DUXY3W0GQR1XS
NCCIT	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf4dJhKSzVyPUmuOVMyPjlizszN	MnGzV2FPT0WU
SAS	M37wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XnbWlEPTB;MUCuNlQ5KM7:TR?=	NG\wVGlUSU6JRWK=
A673	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3f2NmlEPTB;MUCuN\|cxPCEQvF2=	MW\TRW5ITVJ?
NCI-H1522	M3nKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\TSHpKSzVyPUGwMlM4ODdizszN	NULlOIlHW0GQR1XS
NCI-H810	NUjxR4xnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPaT\|hKSzVyPUGwMlM6ODdizszN	M17qXnNCVkeHUh?=
IST-MES1	M3\QNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\2eGlEPTB;MUCuOFU3PCEQvF2=	NX;jU3NPW0GQR1XS
GR-ST	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf6XlVKSzVyPUGwMlUxOjRizszN	NGLISWhUSU6JRWK=
SUP-T1	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2roe2lEPTB;MUCuO\|MyPyEQvF2=	MV7TRW5ITVJ?
NB5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PZUGlEPTB;MUCuPVAzOiEQvF2=	NXPzbYczW0GQR1XS
MZ1-PC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LDOmlEPTB;MUCuPVU4OSEQvF2=	MkfIV2FPT0WU
SK-CO-1	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfuTWM2OD1zMD65PVMyKM7:TR?=	M3PDPXNCVkeHUh?=
Capan-2	NUW4OlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVflWoxOUUN3ME2xNU4{OTl6IN88US=>	MoTQV2FPT0WU
697	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[z[W1KSzVyPUGxMlY4PTdizszN	M2HCcnNCVkeHUh?=
REH	M3zJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWX3W3VDUUN3ME2xNU44PDVzIN88US=>	NVXSToJuW0GQR1XS
GI-1	NGSzTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LvVGlEPTB;MUGuPFYyPSEQvF2=	M{LRfXNCVkeHUh?=
BB65-RCC	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;n[\|hEUUN3ME2xNk4xQTF4IN88US=>	NVjRZmpnW0GQR1XS
NCI-H1651	Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF{LkK0O\|gh\|ryP	MWDTRW5ITVJ?
NCI-H1618	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDSTWM2OD1zMj6zPVc3KM7:TR?=	MUnTRW5ITVJ?
NCI-H2081	NIPoNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHm4XIhKSzVyPUGyMlYyPDFizszN	M{j0N3NCVkeHUh?=
GCIY	NFTRTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XMe2lEPTB;MUKuO\|IyOyEQvF2=	MYfTRW5ITVJ?
NY	NYnab5g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPjSnZKSzVyPUGzMlA3PDNizszN	NF7xVVNUSU6JRWK=
PANC-03-27	M2\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mySWlEPTB;MUOuNFgxPyEQvF2=	NYDFZ246W0GQR1XS
BHY	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHGblBKSzVyPUGzMlIyOjFizszN	M134eXNCVkeHUh?=
SK-OV-3	M{fWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLUZ2hKSzVyPUGzMlM4PjNizszN	M1rQd3NCVkeHUh?=
5637	NID3RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTsd3Y1UUN3ME2xN{44PzV7IN88US=>	Mmr4V2FPT0WU
LC-1F	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP0SnpKSzVyPUG0MlA{PTZizszN	M4O0cnNCVkeHUh?=
SNB75	M2W4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvJdWZrUUN3ME2xOE4xOzh\|IN88US=>	M1vmNXNCVkeHUh?=
CHP-212	NGXGN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\4T2lEPTB;MUSuNFQ3PCEQvF2=	NGHVbZJUSU6JRWK=
HT-1376	MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG5cW1KSzVyPUG0MlEyOjZizszN	M4\T[XNCVkeHUh?=
MONO-MAC-6	M1HEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nRO2lEPTB;MUSuNVUxOiEQvF2=	NVfVZohoW0GQR1XS
CA46	NFP0S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjNTWM2OD1zND6xPFI4KM7:TR?=	NG\WUI9USU6JRWK=
SCC-15	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\VTWM2OD1zND61OVg{KM7:TR?=	NVnZeXRnW0GQR1XS
ATN-1	M3LMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLlTWM2OD1zND62OlI4KM7:TR?=	MmjRV2FPT0WU
NCI-H2405	M2fwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPwTWM2OD1zND64NVU4KM7:TR?=	MknvV2FPT0WU
NCI-H716	NYewcHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkL0TWM2OD1zND64OFk{KM7:TR?=	NH3pNllUSU6JRWK=
SW620	NYLBOoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PvNmlEPTB;MUSuPVAyPCEQvF2=	MmnaV2FPT0WU
NCI-H226	M1TZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\4N2FpUUN3ME2xOE46ODh3IN88US=>	M3X3b3NCVkeHUh?=
SW962	NHXIVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT5SY5oUUN3ME2xOE46PDN{IN88US=>	NHXNOIFUSU6JRWK=
KYSE-150	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPlTYtKSzVyPUG0Mlk2PSEQvF2=	NELDVGhUSU6JRWK=
OCUB-M	M2H0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLzfHp7UUN3ME2xOE46QDh\|IN88US=>	M1uwZnNCVkeHUh?=
ES7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nhUmlEPTB;MUWuNFk5PCEQvF2=	NGLjVHVUSU6JRWK=
SW1463	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF3LkSyNlMh\|ryP	MWLTRW5ITVJ?
CAKI-1	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnMb5o6UUN3ME2xOU42OzR4IN88US=>	MUPTRW5ITVJ?
MKN28	M1rHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7ublRKSzVyPUG1MlU1PzlizszN	NXv3PWFKW0GQR1XS
SW13	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXF[mdEUUN3ME2xOU43OThizszN	Mn35V2FPT0WU
A3-KAW	NXz2XnBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTF3Lkm2PVch\|ryP	NULQV5V5W0GQR1XS
LU-65	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTF3Lkm3Olgh\|ryP	M4DTTHNCVkeHUh?=
Calu-1	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHWTWM2OD1zNj6wN\|Y5KM7:TR?=	Ml\4V2FPT0WU
ST486	NWDt[nhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTF4LkC0N\|Eh\|ryP	NX;jRYF1W0GQR1XS
BB30-HNC	NYnq[GJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfVdnNKSzVyPUG2MlEzPDZizszN	MXvTRW5ITVJ?
EGI-1	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HHb2lEPTB;MU[uOFQ3KM7:TR?=	MnLnV2FPT0WU
SH-4	NFrwVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{S3[mlEPTB;MU[uOFc{OSEQvF2=	MlW0V2FPT0WU
MN-60	M2SxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\iTWM2OD1zNz6yNlk4KM7:TR?=	MXXTRW5ITVJ?
MPP-89	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXpTWM2OD1zNz6yOFU6KM7:TR?=	M17KdHNCVkeHUh?=
A2780	M37jTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTF5LkSxN\|kh\|ryP	NFm0XWpUSU6JRWK=
Daoy	NXrqS2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPUZlFKSzVyPUG3MlQ3QTVizszN	Mn;2V2FPT0WU
NCI-H2126	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjoOG9XUUN3ME2xO{41PzdzIN88US=>	M3TXZ3NCVkeHUh?=
NCI-H1563	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTYb4NDUUN3ME2xO{41QTF5IN88US=>	MlfnV2FPT0WU
8-MG-BA	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTBTWM2OD1zNz62OlQ5KM7:TR?=	MXvTRW5ITVJ?
786-0	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonWTWM2OD1zNz64N\|U{KM7:TR?=	M2LvOnNCVkeHUh?=
AM-38	NFSzOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTF5LkmzNFYh\|ryP	MV7TRW5ITVJ?
COLO-824	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPrWXdKSzVyPUG4MlQ1OzZizszN	MUjTRW5ITVJ?
SK-MEL-30	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jkcWlEPTB;MUiuOVA5OiEQvF2=	MkLGV2FPT0WU
CESS	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjJfJFKSzVyPUG4Mlc3ODlizszN	NWHoUYlpW0GQR1XS
BL-70	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH2TWM2OD1zOD64NVU3KM7:TR?=	M1nO[3NCVkeHUh?=
NCI-H2170	NV3YN2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\FZ3hvUUN3ME2xPE46OTd7IN88US=>	NEDRPYRUSU6JRWK=
HT-3	NVPWU5lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnJSpNVUUN3ME2xPE46QDNizszN	NH7yOY9USU6JRWK=
BOKU	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXv3WGtuUUN3ME2xPU4xOzhzIN88US=>	MVnTRW5ITVJ?
HPAF-II	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTF7LkOwNVUh\|ryP	M2nyPHNCVkeHUh?=
KGN	NHXPPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zYc2lEPTB;MUmuOFc3PSEQvF2=	NV[xUXR[W0GQR1XS
MC-CAR	NXfqTVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkn2TWM2OD1zOT62N\|E{KM7:TR?=	MmSxV2FPT0WU
BHT-101	NFrVcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L0cGlEPTB;MUmuO\|c4KM7:TR?=	M4nZW3NCVkeHUh?=
SW1783	NIKwU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfSTWM2OD1zOT63PFA3KM7:TR?=	M4D5RXNCVkeHUh?=
KP-N-YN	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTJyLkCyOlIh\|ryP	MYXTRW5ITVJ?
LU-165	M4HMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHSwbYdKSzVyPUKwMlU2PzFizszN	NIC2NoRUSU6JRWK=
GOTO	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTJyLk[0OVEh\|ryP	NF\JboZUSU6JRWK=
EFM-19	M1TJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTJzLkC3NVYh\|ryP	MVjTRW5ITVJ?
CTV-1	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXxd2VrUUN3ME2yNU4yODV2IN88US=>	MlHOV2FPT0WU
HEL	M4T4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjxTVBKSzVyPUKxMlQzOTZizszN	M4faenNCVkeHUh?=
SNU-C2B	NV:y[Y5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[ycINZUUN3ME2yNU41OjZizszN	NHfXbFZUSU6JRWK=
ECC4	M3fNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml2wTWM2OD1{MT63NFch\|ryP	NEj6WpRUSU6JRWK=
NEC8	M{LuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTJzLkizOlgh\|ryP	NGe0V4RUSU6JRWK=
KMOE-2	M4rU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\nTWM2OD1{MT64PVIyKM7:TR?=	NVL4Tmo6W0GQR1XS
NCI-H524	M1jiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTJ{LkC4NFgh\|ryP	MnOwV2FPT0WU
WSU-NHL	NEfYV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYC5cXlCUUN3ME2yNk4yPTd5IN88US=>	NXjOWHA5W0GQR1XS
SF126	NYH2bm9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq3e5UxUUN3ME2yNk4zPDZ7IN88US=>	M4LpOnNCVkeHUh?=
HOP-92	NGnoTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3zcJhlUUN3ME2yNk4{OTZ5IN88US=>	MmPoV2FPT0WU
CTB-1	M2XQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTJ{LkS2O\|ch\|ryP	MlHEV2FPT0WU
KYSE-270	NGriR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTJ{LkmzOVch\|ryP	M4PwUXNCVkeHUh?=
SK-MEL-24	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTJ\|LkG4O{DPxE1?	NXvxdYxmW0GQR1XS
Calu-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDy[ndKSzVyPUKzMlIyOjhizszN	MUjTRW5ITVJ?
GAMG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm4N2ttUUN3ME2yN{4zOzZ5IN88US=>	MmDFV2FPT0WU
SW1573	NUnUblU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7oTWM2OD1{Mz63OFE2KM7:TR?=	Mmm5V2FPT0WU
MHH-NB-11	NYWwSG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfVbmI2UUN3ME2yOE4xOTl2IN88US=>	NUjoOJJRW0GQR1XS
TK10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1yyemlEPTB;MkSuOVAyOyEQvF2=	MlPYV2FPT0WU
LB373-MEL-D	NF\tRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7JbFNzUUN3ME2yOE43ODZ2IN88US=>	M4jER3NCVkeHUh?=
KALS-1	NG\iN\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDHWFhKSzVyPUK0Mlc{OjdizszN	M{nDTnNCVkeHUh?=
HUTU-80	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTJ3LkiwN\|Ih\|ryP	NXL6O2Q3W0GQR1XS
HuP-T3	NVfZNolzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nOOmlEPTB;Mk[uNVY4PCEQvF2=	M3vWbHNCVkeHUh?=
OE19	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUn5doVuUUN3ME2yOk4zOTV\|IN88US=>	M1;MOnNCVkeHUh?=
J82	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTJ4LkK0O\|Eh\|ryP	MY\TRW5ITVJ?
DU-4475	M4DPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\qTWM2OD1{Nj6zPFE6KM7:TR?=	M1rOWXNCVkeHUh?=
DMS-53	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHMRZJxUUN3ME2yOk42OTN6IN88US=>	MkLxV2FPT0WU
COLO-741	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NESxSmJKSzVyPUK2Mlg{PDRizszN	NGK2[plUSU6JRWK=
SW48	M4nh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELHe\|NKSzVyPUK2Mlg5OiEQvF2=	Ml;jV2FPT0WU
IGR-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVy1Omk{UUN3ME2yOk46OzN2IN88US=>	M3PpW3NCVkeHUh?=
639-V	NEP4[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfMcohXUUN3ME2yO{4xOjR3IN88US=>	NF7KSVVUSU6JRWK=
LK-2	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r5XWlEPTB;MkeuOFE1OSEQvF2=	Mn3ZV2FPT0WU
NCI-H2347	NU\BTWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjT[I1qUUN3ME2yO{46Pjl7IN88US=>	NHrVcFlUSU6JRWK=
NCI-H2228	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjoU4NKSzVyPUK4MlA6ODVizszN	M2XOOXNCVkeHUh?=
LS-123	NEnqe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfETWM2OD1{OD6xNlYzKM7:TR?=	NFXPfZhUSU6JRWK=
U031	NUToeW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33temlEPTB;MkiuNlUzKM7:TR?=	NUP3TG9SW0GQR1XS
NCI-H1792	NIi3Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJ6LkS3NlEh\|ryP	MlLVV2FPT0WU
NCI-H2087	NYXuWoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmW4TWM2OD1{OD63OVUzKM7:TR?=	MX\TRW5ITVJ?
NCI-H2342	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfwb\|RKSzVyPUK5MlUzODhizszN	NUiwTGliW0GQR1XS
SW626	NFPCS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn34TWM2OD1{OT63OVYh\|ryP	MYfTRW5ITVJ?
LB2518-MEL	M1PaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7yV5E{UUN3ME2yPU45OTVizszN	M1mzZnNCVkeHUh?=
RXF393	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jlOmlEPTB;M{CuNFk2OiEQvF2=	M3y2e3NCVkeHUh?=
LC4-1	M{D1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH32W41KSzVyPUOwMlMxQTJizszN	MWDTRW5ITVJ?
NCI-H1694	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfrcWJKSzVyPUOwMlY3OjRizszN	NI\3cnVUSU6JRWK=
K5	NHG5e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\MdWlEPTB;M{CuPVcxOiEQvF2=	NGfDS2FUSU6JRWK=
HDLM-2	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHU[mRKSzVyPUOwMlk4OjVizszN	M{nZT3NCVkeHUh?=
BCPAP	NYTZVINiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\5bGlEPTB;M{GuPFM4QSEQvF2=	M2DIcHNCVkeHUh?=
BC-3	NXu1NZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mor2TWM2OD1\|Mj6xOFA{KM7:TR?=	MYjTRW5ITVJ?
LB996-RCC	NGHhW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:2ZWlEPTB;M{KuNlM2QCEQvF2=	NHWxNoJUSU6JRWK=
NCI-H2009	NFPwXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTN{LkS5PFEh\|ryP	MoC1V2FPT0WU
HTC-C3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;KSVRKSzVyPUOzMlc2OTlizszN	MnixV2FPT0WU
LAMA-84	NW\uR41UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PnOWlEPTB;M{SuOFQxPyEQvF2=	M3jJbXNCVkeHUh?=
CCRF-CEM	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HQWGlEPTB;M{SuOVcyPSEQvF2=	M1z5XHNCVkeHUh?=
AN3-CA	M{LTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml64TWM2OD1\|NT6wOVY5KM7:TR?=	NX;EUnRkW0GQR1XS
NCI-H1734	NFPkT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTN3LkK1OlEh\|ryP	MmPUV2FPT0WU
Ca-Ski	NWmySHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTN3LkSxNFEh\|ryP	MlzXV2FPT0WU
U-266	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4npbWlEPTB;M{WuOlEyPCEQvF2=	NWLISYs1W0GQR1XS
SBC-5	NH\UVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTN3Lke3PFEh\|ryP	NILw[mRUSU6JRWK=
GT3TKB	NHi4cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTN5LkGxOUDPxE1?	M1XLSHNCVkeHUh?=
MDA-MB-175-VII	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUS2[4s{UUN3ME2zO{4zOjR6IN88US=>	NXr3VVM3W0GQR1XS
PFSK-1	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTN5LkK0N\|Uh\|ryP	M3PPXXNCVkeHUh?=
IMR-5	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj5TWViUUN3ME2zO{4zPDh5IN88US=>	NUjQbpNjW0GQR1XS
Daudi	NGP3d2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjxTWM2OD1\|Nz6zOVk4KM7:TR?=	MnrGV2FPT0WU
A498	NF7kZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfvNJpKSzVyPUO3MlczOThizszN	MX7TRW5ITVJ?
SCC-4	NEXuRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTN5Lke4OFMh\|ryP	M1PqPHNCVkeHUh?=
COLO-680N	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPUTWM2OD1\|OD6yPFg2KM7:TR?=	Mn\OV2FPT0WU
SK-MES-1	NWnEfHdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTN6LkOyNVUh\|ryP	MXHTRW5ITVJ?
SR	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDsdHl6UUN3ME2zPE42PDl3IN88US=>	Mki2V2FPT0WU
LNCaP-Clone-FGC	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq5XFhFUUN3ME2zPE42PjN5IN88US=>	M1zBTnNCVkeHUh?=
SK-HEP-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnZdJZ{UUN3ME2zPE44QDJ{IN88US=>	NV3CS4lFW0GQR1XS
BPH-1	NUPBcIt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTN6LkizNlkh\|ryP	NHq4U4dUSU6JRWK=
NCI-H1755	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnkTXMzUUN3ME2zPU42QDF5IN88US=>	NE\pSoVUSU6JRWK=
LXF-289	M2H1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrs[2ZDUUN3ME2zPU45ODh2IN88US=>	MVzTRW5ITVJ?
SW1088	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDsTWM2OD12MD6yNVA4KM7:TR?=	NXvHfIxtW0GQR1XS
MOLT-4	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzW[Xp[UUN3ME20NE4zQTBzIN88US=>	MV;TRW5ITVJ?
AsPC-1	NVP0bJUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\WfG1KSzVyPUSwMlQ2QDNizszN	MU\TRW5ITVJ?
HOP-62	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTRyLk[1Olgh\|ryP	Mn;RV2FPT0WU
A172	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjnbVlSUUN3ME20NE45PTFzIN88US=>	NIfa[3pUSU6JRWK=
SN12C	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTRyLkmzPFUh\|ryP	M4XQTHNCVkeHUh?=
MDA-MB-231	NYfEfJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvKOFdKSzVyPUSwMlk5QThizszN	NVHWV45vW0GQR1XS
RPMI-2650	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTRzLkG1PVMh\|ryP	MojnV2FPT0WU
KYSE-140	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnIXlE1UUN3ME20NU45OTJ\|IN88US=>	NHPSVIlUSU6JRWK=
KINGS-1	NIXQRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPJTWM2OD12Mj60Olk4KM7:TR?=	MVnTRW5ITVJ?
HSC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnj[JlKSzVyPUSyMlY3PjFizszN	MlrLV2FPT0WU
PC-14	NF7nTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnzVZVKSzVyPUSzMlE5QDJizszN	NYTGWmpCW0GQR1XS
COR-L105	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vBRWlEPTB;NEOuOlUxOiEQvF2=	MoX3V2FPT0WU
BE-13	M{DsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnG4TWM2OD12ND6yN\|cyKM7:TR?=	NGHXSHBUSU6JRWK=
NCI-H661	M13XTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH1T5poUUN3ME20OE4zQTV6IN88US=>	M4DrZnNCVkeHUh?=
IST-MEL1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XNU2lEPTB;NESuN\|U6QSEQvF2=	Ml;ZV2FPT0WU
HCC1806	NWHmXYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGO4c3JKSzVyPUS0MlU5PzNizszN	MUnTRW5ITVJ?
COLO-800	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfJWYNKSzVyPUS0Mlg1PTNizszN	NHTyT5dUSU6JRWK=
IST-SL2	NX\XR2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1j2PGlEPTB;NEWuNVI1PyEQvF2=	NEGyTWNUSU6JRWK=
8305C	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7XZ2xVUUN3ME20OU4{ODlizszN	NGjxVHJUSU6JRWK=
UACC-62	M4HhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTZNnlrUUN3ME20Ok4zQDd3IN88US=>	MkXoV2FPT0WU
COR-L23	NHPBflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\lW2lEPTB;NEeuNVk6KM7:TR?=	MoP0V2FPT0WU
EFE-184	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTR5LkO4PEDPxE1?	MkLnV2FPT0WU
DMS-114	NV3EemtVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXviV2xEUUN3ME20O{41OTR7IN88US=>	MUjTRW5ITVJ?
KYSE-520	NGjYeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rXUWlEPTB;NEiuOVMyPSEQvF2=	Mn\UV2FPT0WU
SNG-M	M4T5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHqxXJpKSzVyPUS5MlQ{PCEQvF2=	NF\ieGdUSU6JRWK=
A2058	M3fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;FdGlEPTB;NEmuOFg5PSEQvF2=	MoD3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Formulation: 25 mM tartaric acid Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CC1(O)CC(C1)C2=NC(=C3[N]2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Bemcentinib（R428) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)